Pharmaceutical companies prioritize lucrative weight-loss drugs, causing insulin shortages, impacting millions of diabetic patients like Skye Murphy who faces potential health risks due to delays in receiving medication.
Eli Lilly, Novo Nordisk, and Sanofi control 75% of the global insulin market, with Eli Lilly admitting a shortage due to manufacturing delays, leaving patients like Murphy rationing doses and struggling to find refills to avoid severe health issues.
[
add
]
[
|
|
...
]